Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest 1 selected

Area of interest

Type

Type

Guidance programme

Showing 1 to 10 of 10

TitleType
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaMedical technologies guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All